Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

34 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
SER-109, an Oral Microbiome Therapy for Recurrent Clostridioides difficile Infection.
Feuerstadt P, Louie TJ, Lashner B, Wang EEL, Diao L, Bryant JA, Sims M, Kraft CS, Cohen SH, Berenson CS, Korman LY, Ford CB, Litcofsky KD, Lombardo MJ, Wortman JR, Wu H, Auniņš JG, McChalicher CWJ, Winkler JA, McGovern BH, Trucksis M, Henn MR, von Moltke L. Feuerstadt P, et al. Among authors: trucksis m. N Engl J Med. 2022 Jan 20;386(3):220-229. doi: 10.1056/NEJMoa2106516. N Engl J Med. 2022. PMID: 35045228 Clinical Trial.
SER-109, an Investigational Microbiome Drug to Reduce Recurrence After Clostridioides difficile Infection: Lessons Learned From a Phase 2 Trial.
McGovern BH, Ford CB, Henn MR, Pardi DS, Khanna S, Hohmann EL, O'Brien EJ, Desjardins CA, Bernardo P, Wortman JR, Lombardo MJ, Litcofsky KD, Winkler JA, McChalicher CWJ, Li SS, Tomlinson AD, Nandakumar M, Cook DN, Pomerantz RJ, Auninš JG, Trucksis M. McGovern BH, et al. Among authors: trucksis m. Clin Infect Dis. 2021 Jun 15;72(12):2132-2140. doi: 10.1093/cid/ciaa387. Clin Infect Dis. 2021. PMID: 32255488 Free PMC article. Clinical Trial.
A Phase 1b Safety Study of SER-287, a Spore-Based Microbiome Therapeutic, for Active Mild to Moderate Ulcerative Colitis.
Henn MR, O'Brien EJ, Diao L, Feagan BG, Sandborn WJ, Huttenhower C, Wortman JR, McGovern BH, Wang-Weigand S, Lichter DI, Chafee M, Ford CB, Bernardo P, Zhao P, Simmons S, Tomlinson AD, Cook DN, Pomerantz RJ, Misra BK, Auninš JG, Trucksis M. Henn MR, et al. Among authors: trucksis m. Gastroenterology. 2021 Jan;160(1):115-127.e30. doi: 10.1053/j.gastro.2020.07.048. Epub 2020 Aug 4. Gastroenterology. 2021. PMID: 32763240 Free PMC article. Clinical Trial.
A single supratherapeutic dose of ridaforolimus does not prolong the QTc interval in patients with advanced cancer.
Lush RM, Patnaik A, Sullivan D, Papadopoulos KP, Trucksis M, McCrea J, Cerchio K, Li X, Stroh M, Selverian D, Orford K, Ebbinghaus S, Agrawal N, Iwamoto M, Wagner JA, Tolcher A. Lush RM, et al. Among authors: trucksis m. Cancer Chemother Pharmacol. 2012 Oct;70(4):567-74. doi: 10.1007/s00280-012-1942-7. Epub 2012 Aug 10. Cancer Chemother Pharmacol. 2012. PMID: 22878520 Free PMC article. Clinical Trial.
The effect of multiple doses of rifampin and ketoconazole on the single-dose pharmacokinetics of ridaforolimus.
Stroh M, Palcza J, McCrea J, Marsilio S, Breidinger S, Panebianco D, Johnson-Levonas A, Kraft WK, Orford K, Murphy G, Agrawal N, Trucksis M, Wagner JA, Iwamoto M. Stroh M, et al. Among authors: trucksis m. Cancer Chemother Pharmacol. 2012 May;69(5):1247-53. doi: 10.1007/s00280-011-1819-1. Cancer Chemother Pharmacol. 2012. PMID: 22290273 Clinical Trial.
The minimal impact of food on the pharmacokinetics of ridaforolimus.
Stroh M, Li X, Marsilio S, Panebianco D, Johnson-Levonas A, Juan A, Orford K, Agrawal N, Trucksis M, Wagner JA, Murphy G, Iwamoto M. Stroh M, et al. Among authors: trucksis m. Cancer Chemother Pharmacol. 2012 Jul;70(1):177-82. doi: 10.1007/s00280-012-1897-8. Epub 2012 Jun 6. Cancer Chemother Pharmacol. 2012. PMID: 22669570 Clinical Trial.
Lack of meaningful effect of ridaforolimus on the pharmacokinetics of midazolam in cancer patients: model prediction and clinical confirmation.
Stroh M, Talaty J, Sandhu P, McCrea J, Patnaik A, Tolcher A, Palcza J, Orford K, Breidinger S, Narasimhan N, Panebianco D, Lush R, Papadopoulos KP, Wagner JA, Trucksis M, Agrawal N. Stroh M, et al. Among authors: trucksis m. J Clin Pharmacol. 2014 Nov;54(11):1256-62. doi: 10.1002/jcph.331. Epub 2014 May 24. J Clin Pharmacol. 2014. PMID: 24827931 Clinical Trial.
UGT2B17 genetic polymorphisms dramatically affect the pharmacokinetics of MK-7246 in healthy subjects in a first-in-human study.
Wang YH, Trucksis M, McElwee JJ, Wong PH, Maciolek C, Thompson CD, Prueksaritanont T, Garrett GC, Declercq R, Vets E, Willson KJ, Smith RC, Klappenbach JA, Opiteck GJ, Tsou JA, Gibson C, Laethem T, Panorchan P, Iwamoto M, Shaw PM, Wagner JA, Harrelson JC. Wang YH, et al. Among authors: trucksis m. Clin Pharmacol Ther. 2012 Jul;92(1):96-102. doi: 10.1038/clpt.2012.20. Epub 2012 Jun 6. Clin Pharmacol Ther. 2012. PMID: 22669291 Free PMC article. Clinical Trial.
Preclinical Pharmacokinetics and Pharmacodynamic Target of SCY-078, a First-in-Class Orally Active Antifungal Glucan Synthesis Inhibitor, in Murine Models of Disseminated Candidiasis.
Wring SA, Randolph R, Park S, Abruzzo G, Chen Q, Flattery A, Garrett G, Peel M, Outcalt R, Powell K, Trucksis M, Angulo D, Borroto-Esoda K. Wring SA, et al. Among authors: trucksis m. Antimicrob Agents Chemother. 2017 Mar 24;61(4):e02068-16. doi: 10.1128/AAC.02068-16. Print 2017 Apr. Antimicrob Agents Chemother. 2017. PMID: 28137806 Free PMC article.
The American cotton rat: a novel model for pulmonary tuberculosis.
Elwood RL, Wilson S, Blanco JC, Yim K, Pletneva L, Nikonenko B, Samala R, Joshi S, Hemming VG, Trucksis M. Elwood RL, et al. Among authors: trucksis m. Tuberculosis (Edinb). 2007 Mar;87(2):145-54. doi: 10.1016/j.tube.2006.07.001. Epub 2006 Sep 12. Tuberculosis (Edinb). 2007. PMID: 16973421
34 results